4 in the placebo arm ( Janssen et al., 2013). Undetectable HCV RNA was achieved in one patient in the 5-mg group

and in four patients http://www.selleckchem.com/products/CP-690550.html in the 7-mg group. Levels of virus rebounded in most patients who were not treated with PR therapy. One patient, a 43 year old female with fibrosis stage F0–F1 and HCV genotype 1b infection who was dosed with miravirsen 7 mg/kg, became HCV RNA negative at study week 14 and remained this for a period of at least 15 weeks without the initiation of PR therapy ( Fig. 1). This patient was followed up frequently and experienced a virological relapse 44 weeks after miravirsen dosing, at which time the HCV RNA level (log10 IU/mL) was 4.37 and the ALT level (IU/L) was 109. Two weeks after the virological relapse, the HCV RNA level decreased to 3.83

with a simultaneous decrease in ALT level to 62. However, three months later, the viral load and ALT were back at the pre-treatment levels, with a HCV RNA level of 6.12 as compared to 5.92 at baseline and an ALT level of 78 compared to 82 at baseline. Population sequencing showed no nucleotide changes in the 5′UTR or amino acid differences in NS3, NS5A and NS5B regions. PR therapy was started in 14/36 PFI-2 patients of whom 2 received placebo, 5 received 3 mg/kg, 4 received 5 mg/kg and 3 received 7 mg/kg miravirsen (Table 2). The dose of ribavirin was reduced in two patients during treatment due to anaemia and gingival bleeding. SVR was achieved in 7/12 (58%) of the patients previously treated with different doses of miravirsen. All patients (n = 3) who received the highest dose of miravirsen (7 mg/kg) and were treated with PR achieved RVR and SVR. Of these patients, 2/3 had undetectable HCV RNA at the start of PR therapy ( Fig. 2). The median treatment duration of patients who achieved SVR was 24 weeks (IQR 14–48 weeks), ADAMTS5 compared to 47 weeks (IQR 24–48 weeks) in patients without SVR (p = 0.01). Mean HCV RNA levels (log10 IU/mL) at the start of PR therapy were significantly

lower for patients achieving SVR compared to patients who did not achieve SVR, respectively 3.1 versus 5.2 (p = 0.029). The interleukin-28B (IL28B) genotype distribution of patients achieving SVR was CC (n = 1), CT (n = 4) and TT (n = 2). Therapy failed in five patients which was due to non-response (n = 2), virological relapse (n = 2), and virological breakthrough after therapy cessation due to hospitalization for a pneumonia (n = 1) ( Table 2). The IL28B genotype distribution of patients who failed PR therapy was CT (n = 4) and TT (n = 1). Two serious adverse events occurred during PR therapy. One patient was hospitalized due to bronchopneumonia and one patient was observed overnight in the hospital due to loss of consciousness that occurred after a fall. Both events were considered unrelated to miravirsen dosing. Patients were followed up to 35 months after the start of miravirsen therapy, with a median duration of 24 months (IQR 14–28 months).